Delthia Ricks

In 2018, a New York surgeon-scientist and his team demonstrated in a proof-of-concept study that a minimally invasive procedure could effectively treat one of the world's most common conditions requiring neurosurgical intervention.

A longstanding question has nagged the COVID battle for more than four years: Why does the infection cause severe disease in older people? The question has remained despite a global cadre of medical investigators having produced some of the reasons—but not the entire story.

An experimental monoclonal antibody has been engineered to target the deadly Nipah virus, an emerging zoonotic pathogen with a human mortality rate ranging as high as a staggering 90%.

Monoclonal antibodies have become indispensable in medicine to combat cancers, infectious diseases and autoimmune disorders. But the mechanism of action of a major monoclonal antibody developed for ulcerative colitis has remained elusive—until now.

Artificial intelligence is being used in a wide variety of applications in medicine, and now scientists have developed an AI system that can boost detection rates for cancerous and precancerous lesions of the esophagus, which are sometimes difficult for doctors to find.

Medical science has long been on the hunt for a deeper understanding of the devastating scarring of the body's organs known as fibrosis, which leads to irrevocable loss of function.

Five years ago, at the outset of the coronavirus pandemic, a phenomenon became abundantly clear: Preschool-age children rarely developed severe cases of COVID-19.

Few autoimmune disorders are more challenging for patients than multiple sclerosis, a progressive condition that can affect vision, impair the ability to walk, cause extreme bouts of neuropathic pain, and tends to strike women at three times the rate of men.

A critical challenge during the early COVID-19 pandemic was determining whether a patient would survive the infection or die from it. And even though a host of lifesaving therapeutics now spares substantially more lives than four years ago, the art of predicting COVID outcomes remains a matter of scientific pursuit.

A critical challenge during the early COVID-19 pandemic was determining whether a patient would survive the infection or die from it.